The topic of this article may not meet Wikipedia's notability guideline for biographies. (June 2020) |
Mark Pieloch is the President and owner of PF Inc.,[1] formerly known as Pet Flavors.
Mark Pieloch | |
|---|---|
| Born | December 5, 1957 |
| Nationality | American |
| Education | Massachusetts College of Pharmacy University of Michigan |
| Occupation(s) | President and owner of PF Inc. |
Education edit
Mark Pieloch attended Gardner High School in Gardner, Massachusetts. After high school, Pieloch earned a M.S. in Industrial Pharmacy from the Massachusetts College of Pharmacy, and went on to earn a Master of Business Administration from the Ross School of Business of the University of Michigan.[2]
Career edit
Pieloch has been a registered pharmacist in Massachusetts since 1979.[3] He founded a variety of businesses in the field of pet pharmaceuticals, beginning with Pharma Chemie in Lincoln, Nebraska, in 1990.
Since then, he has operated and/or sold PSPC, Phycox, Peak Nutrition, PalaTech Laboratories, and FlavorTek. Pet Flavors (now known as PF Inc.) is his current venture.
In 2016, he created the American Muscle Car Museum in Melbourne, Florida, to house his automobile collection. Featuring more than 400 cars, it is mainly used for charitable fundraising events and is otherwise not open to the public.
Patents edit
Pieloch is named as an inventor or co-inventor on two patents. These are US patents 6780437, issued for coated potassium chloride granules and tablets, and 7025965, issued for a method of use and dosage composition of blue-green algae extract for inflammation in animals.[4]
References edit
- ^ "PF, INC". Florida Companies. Retrieved 10 April 2014.
- ^ "Michigan Ross School of Business Investor Report" (PDF). Michigan Ross School of Business. Retrieved 10 April 2014.
- ^ "Massachusetts Health Care Safety & Quality License Verification Site". Massachusetts Official Website of the Office of Health and Human Services. Retrieved 10 April 2014.
- ^ "Patents by Inventor Mark J. Pieloch". Justia Patents. Retrieved 10 April 2014.